keyword
MENU ▼
Read by QxMD icon Read
search

"Chronic lymphocytic leukemia"

keyword
https://www.readbyqxmd.com/read/29667271/syndrome-and-outcome-of-antibody-negative-limbic-encephalitis
#1
Francesc Graus, Domingo Escudero, Laura Oleaga, Jordi Bruna, Alberto Villarejo-Galende, Jordi Ballabriga, María Inés Barceló, Francisco Gilo, Stoyan Popkirov, Pavel Stourac, Josep Dalmau
OBJECTIVE: To report the clinical characteristics of 12 patients with limbic encephalitis (LE) who were antibody-negative after a comprehensive immunological study. METHODS: Review of clinical records of 163 patients with LE. Immunohistochemistry on rat brain, cultured neurons, and cell-based assays were used to identify neuronal autoantibodies. Patients were included if 1) there was adequate clinical, CSF, and MRI information to classify the syndrome as LE, 2) MRI images were accesible for central review, and 3) serum and CSF were available and confirmed negative for neuronal antibodies...
April 18, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29667176/pre-diagnostic-blood-immune-markers-incidence-and-progression-of-b-cell-lymphoma-and-multiple-myeloma-univariate-and-functionally-informed-multivariate-analyses
#2
Roel Vermeulen, Fatemeh Saberi Hosnijeh, Barbara Bodinier, Lützen Portengen, Benoît Liquet, Javiera Garrido-Manriquez, Henk Lokhorst, Ingvar A Bergdahl, Soterios A Kyrtopoulos, Ann-Sofie Johansson, Panagiotis Georgiadis, Beatrice Melin, Domenico Palli, Vittorio Krogh, Salvatore Panico, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Raphaële Castagné, Marc Chadeau-Hyam
Recent prospective studies have shown that dysregulation of the immune system may precede the development of B-cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case-control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years prior to diagnosis (range, 2.01-15.97) in 268 incident cases of BCL (including multiple myeloma) and matched controls...
April 18, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29666622/chemotactic-cues-for-notch1-dependent-leukemia
#3
REVIEW
Erich Piovan, Valeria Tosello, Alberto Amadori, Paola Zanovello
The NOTCH signaling pathway is a conserved signaling cascade that regulates many aspects of development and homeostasis in multiple organ systems. Aberrant activity of this signaling pathway is linked to the initiation and progression of several hematological malignancies, exemplified by T-cell acute lymphoblastic leukemia (T-ALL). Interestingly, frequent non-mutational activation of NOTCH1 signaling has recently been demonstrated in B-cell chronic lymphocytic leukemia (B-CLL), significantly extending the pathogenic significance of this pathway in B-CLL...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29666114/chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-crossroads-of-genetic-and-microenvironment-interactions
#4
Xose S Puente, Pedro Jares, Elias Campo
Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are two well defined entities that diverge in their basic pathogenic mechanisms and clinical evolution but they share epidemiological characteristics, cells of origin, molecular alterations, and clinical features that differ from other lymphoid neoplasms. CLL and MCL are classically considered indolent and aggressive neoplasms, respectively. However, the clinical evolution of both tumors is very heterogeneous, with subsets of patients having a stable disease for long time whereas others require immediate intervention...
April 17, 2018: Blood
https://www.readbyqxmd.com/read/29665938/-research-and-applications-progress-of-lenalidomide-in-relapsed-refractory-blood-system-diseases-review
#5
Wen-Jing Fan, Zhi-Qiao Fan, Tao Wu, Hai Bai
Lenalidomide, a novel immunomodulatory agent, is a kind of thalidomide derivatives, which shows a good efficacy and safety for hematological system diseases. This review is aimed to evaluate the efficacy and safety of lenalidomide in treatment of patients with multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, classical Hodgkin's lymphoma and POEMS syndrome at their replased or refractory state. At the same time, this review focuses on the newest clinical research and the latest application progress of lenalidomide for relapsed or refractory hematological system diseases...
April 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29659938/mutual-risks-of-cutaneous-melanoma-and-specific-lymphoid-neoplasms-second-cancer-occurrence-and-survival
#6
Megan M Herr, Sara J Schonfeld, Graça M Dores, Diana R Withrow, Margaret A Tucker, Rochelle E Curtis, Lindsay M Morton
Background: It is unclear whether the established association between cutaneous melanoma (CM) and lymphoid neoplasms (LNs) differs across LN subtypes. This study quantifies risk for developing CM after specific LNs and, conversely, for developing specific LNs after CM, as well as assessing clinical impact. Methods: We identified a cohort of Caucasian adults (age 20-83 years) initially diagnosed with CM or LN, as reported to 17 US population-based cancer registries, 2000-2014...
April 6, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29658610/overexpression-of-il-9-induced-by-stat3-phosphorylation-is-mediated-by-mir-155-and-mir-21-in-chronic-lymphocytic-leukemia
#7
Na Chen, Lili Feng, Huiting Qu, Kang Lu, Peipei Li, Xiao Lv, Xin Wang
Interleukin‑9 (IL‑9) can function as both a positive and negative regulator of immune response, however the role of IL‑9 in tumor immunity is poorly understood. Chronic lymphocytic leukemia (CLL) is the most common chronic lympho‑proliferative disorder. Twenty CLL patients from 2010 to 2011 were recruited in the study. Expression and phosphorylation of transcription factor STAT3 and differential microRNAs (miRs) in peripheral blood mononuclear cells (PBMCs) from CLL patient samples were analyzed...
April 12, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29651369/unusual-relapse-of-chronic-lymphocytic-leukemia-after-remission
#8
Wajeeha Rizvi, Quoc Truong
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia with over 20,000 estimated cases in 2017. Leukemic involvement of the nervous system from CLL causing neurologic symptoms is reported in only about one percent of patients. Unfortunately, there is no current standard therapy for the treatment of CLL leptomeningeal disease. In this case, we discuss an unusual presentation of CLL leptomeningeal disease misdiagnosed as chronic rebound headache. A 61-year-old female was diagnosed with Rai stage I CLL in 2002...
February 9, 2018: Curēus
https://www.readbyqxmd.com/read/29650518/secretory-igm-exacerbates-tumor-progression-by-inducing-accumulations-of-mdscs-in-mice
#9
Chih-Hang Anthony Tang, Shiun Chang, Ayumi Hashimoto, Yi-Ju Chen, Chang Won Kang, Anthony R Mato, Juan R Del Valle, Dmitry Gabrilovich, Chih-Chi Andrew Hu
Chronic lymphocytic leukemia cells can secrete immunoglobulin M. However, it is not clear whether secretory IgM (sIgM) plays a role in disease progression. We crossed the Eμ-TCL1 mouse model of CLL, in which the expression of human TCL1 oncogene was driven by the V(H) promoter-Ig(H)-Eμ enhancer, with MD4 mice whose B cells produced B cell receptor (membrane-bound IgM) and sIgM with specificity for hen egg lysozyme (HEL). CLL cells developed in these MD4/Eμ-TCL1 mice reactivated a parental Ig gene allele and secreted IgM, and did not recognize HEL...
April 12, 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29649904/economic-burden-of-treatment-failure-in-chronic-lymphocytic-leukemia-patients
#10
Song Wang, Marie-Hélène Lafeuille, Patrick Lefebvre, Hela Romdhani, Bruno Emond, Mekré Senbetta
OBJECTIVE: This study assessed healthcare costs of first-line treatment failure (TF) in patients with chronic lymphocytic leukemia (CLL), a subtype of non-Hodgkin's lymphoma. METHODS: Pre-diagnosis treatment-naïve adults with ≥2 CLL diagnoses initiated on an antineoplastic agent (index date) after their first CLL diagnosis with ≥12 and ≥6 months of continuous observation pre- and post-index, respectively, were selected from the Truven Health MarketScan® Research Databases...
April 12, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29649100/targeting-the-adenosinergic-axis-in-chronic-lymphocytic-leukemia-a-way-to-disrupt-the-tumor-niche
#11
REVIEW
Tiziana Vaisitti, Francesca Arruga, Silvia Deaglio
Targeting adenosine triphosphate (ATP) metabolism and adenosinergic signaling in cancer is gaining momentum, as increasing evidence is showing their relevance in tumor immunology and biology. Chronic lymphocytic leukemia (CLL) results from the expansion of a population of mature B cells that progressively occupies the bone marrow (BM), the blood, and peripheral lymphoid organs. Notwithstanding significant progress in the treatment of these patients, the cure remains an unmet clinical need, suggesting that novel drugs or drug combinations are needed...
April 12, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29628774/management-of-relapsed-refractory-marginal-zone-lymphoma-focus-on-ibrutinib
#12
REVIEW
Nathan M Denlinger, Narendranath Epperla, Basem M William
Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which are derived from B-cells. The disease subtypes are recognized extranodal, nodal, and splenic MZLs. The disease characteristics, clinical course, and treatment vary considerably based on the site of involvement. In 2017, the US Food and Drug Administration approved ibrutinib, a first in class Bruton's tyrosine kinase inhibitor that revolutionized the care of chronic lymphocytic leukemia patients; for, the treatment of relapsed/refractory MZL based on pivotal open-label Phase II trial demonstrated an overall response rate of 48%, with a complete response rate of 3%, median progression-free survival of 14...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29616852/rituximab-addition-to-chemotherapy-in-real-world-patients-with-chronic-lymphocytic-leukemia-effective-in-first-line-but-indication-of-lack-of-efficacy-in-subsequent-lines-of-therapy
#13
Lina van der Straten, Avinash G Dinmohamed, Peter E Westerweel, Anton W Langerak, Jurgen Riedl, Jeanette K Doorduijn, Arnon P Kater, Mark-David Levin
No abstract text is available yet for this article.
April 4, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29610115/a-phase-1-study-of-lenalidomide-and-ibrutinib-in-combination-with-rituximab-in-relapsed-and-refractory-cll
#14
Chaitra Ujjani, Hongkun Wang, Alan Skarbnik, Neel Trivedi, Pari Ramzi, Nadia Khan, Bruce D Cheson
Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL) include the addition of targeted therapies. The combination of lenalidomide and rituximab demonstrated an overall response rate (ORR) of 66% with a complete response (CR) of 12% in the relapsed/refractory setting. Based on these data, we conducted a phase 1 study of rituximab (R), lenalidomide (L), and ibrutinib (I) in relapsed/refractory CLL. Patients received R 375 mg/m2 cycles 1 to 6 day 1, L on cycles 1 to 12 days 1 to 21, and I until disease progression...
April 10, 2018: Blood Advances
https://www.readbyqxmd.com/read/29608741/critically-elevated-potassium-in-a-55-year-old-female-with-chronic-lymphocytic-leukemia
#15
Jing Cao, Amy B Karger
Hyperkalemia in specimens from patients with chronic lymphocytic leukemia (CLL) may be due to tumor lysis syndrome (TLS) or specimen processing. This report describes a 55-year-old Caucasian woman with CLL who presented to an outside hospital with hyperkalemia and was transferred to a second hospital. Initial evaluation on the core laboratory chemistry analyzer (the VITROS 5600) and the ABL90 FLEX blood gas analyzer showed markedly elevated levels of potassium (K+). TLS was subsequently diagnosed, and dialysis was initiated...
March 28, 2018: Laboratory Medicine
https://www.readbyqxmd.com/read/29599682/paraneoplastic-pemphigus-with-anti-desmocollin-3-autoantibodies-and-chronic-lymphocytic-leukemia
#16
Alicja Adaszewska, Norito Ishii, Jadwiga Dwilewicz-Trojaczek, Katarzyna Woźniak, Takashi Hashimoto, Cezary Kowalewski
No abstract text is available yet for this article.
February 2018: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/29595064/accelerating-drug-development-in-pediatric-cancer-a-novel-phase-i-study-design-of-venetoclax-in-relapsed-refractory-malignancies
#17
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, Mignon L Loh, Lia Gore, Daniel A Morgenstern, Yeshwant Sanzgiri, David Hoffman, Ying Zhou, Jeremy A Ross, Betty Prine, Mohamad Shebley, Megan McNamee, Thalia Farazi, Su Young Kim, Maria Verdugo, Leanne Lash-Fleming, C Michel Zwaan, Josef Vormoor
Venetoclax is a highly selective, potent BCL-2 inhibitor that is approved for some patients previously treated for chronic lymphocytic leukemia, and has shown promising activity in adult studies across several hematologic malignancies. Preclinical studies have demonstrated venetoclax activity in pediatric patient-derived xenograft models and cell lines; however, clinical studies in pediatric patients have yet to be conducted. The prognosis is poor for children with most relapsed/refractory malignancies, and limited treatment options result in unmet clinical need...
March 29, 2018: Future Oncology
https://www.readbyqxmd.com/read/29589978/zap70-expression-enhances-chemokine-driven-chronic-lymphocytic-leukemia-cell-migration-and-arrest-by-valency-regulation-of-integrins
#18
Julia M Laufer, Ruth Lyck, Daniel F Legler
The ζ-associated protein of 70 kDa (ZAP70) is expressed in the aggressive form of B-cell chronic lymphocytic leukemia (CLL). Moreover, the integrin very late antigen (VLA)-1 is highly expressed on subtypes of CLL that are associated with high proliferation rates in the lymph node context. We herein identify a critical role for ZAP70 in chemokine-mediated, inside-out signaling to integrins in trisomy 12 carrying Ohio State University-CLL cell lines derived from a patient with previously treated CLL. We found that ZAP70-positive CLL cells migrated significantly better toward ligands of the lymph node homing chemokine receptors CCR7 and CXCR4 compared with ZAP70-negative cells...
March 28, 2018: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/29588545/validation-of-a-biological-score-to-predict-response-in-chronic-lymphocytic-leukemia-patients-treated-front-line-with-bendamustine-and-rituximab
#19
Massimo Gentile, Tait D Shanafelt, Gianluigi Reda, Francesca Romana Mauro, Katja Zirlik, Stefania Ciolli, Luca Laurenti, Maria Ilaria Del Principe, Davide Rossi, Nicola Di Renzo, Stefano Molica, Francesco Angrilli, Marta Coscia, Annalisa Chiarenza, Annamaria Giordano, Giovanna Cutrona, Kari G Chaffee, Sameer A Parikh, Giuseppina Uccello, Idanna Innocenti, Giovanni Tripepi, Graziella D'Arrigo, Ernesto Vigna, Anna Grazia Recchia, Yair Herishanu, Lev Shvidel, Tamar Tadmor, Agostino Cortelezzi, Giovanni Del Poeta, Gianluca Gaidano, Francesco Di Raimondo, Antonino Neri, Manlio Ferrarini, Robin Foà, Aaron Polliack, Fortunato Morabito
No abstract text is available yet for this article.
March 20, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29587287/cohesin-rad21-gene-promoter-methylation-in-patients-with-chronic-lymphocytic-leukemia
#20
Agapi Ioannidou, Sophia Zachaki, Maria Karakosta, Aggeliki Daraki, Paraskevi Roussou, Kalliopi N Manola
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults and is characterized by the presence of specific cytogenetic abnormalities. CLL research has been focused on epigenetic processes like gene promoter methylation of CpG islands. In the present study, the methylation status of the RAD21 gene is studied and associated with cytogenetic findings in CLL patients in order to investigate its possible implication in CLL pathogenesis and the formation of CLL chromosomal abnormalities.
March 24, 2018: Cytogenetic and Genome Research
keyword
keyword
108143
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"